Trial Profile
A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2023
Price :
$35
*
At a glance
- Drugs Abaloparatide (Primary) ; Bevacizumab (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 20 Jan 2023 Status changed from active, no longer recruiting to completed.
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 10 Aug 2022 Planned End Date changed from 15 Jun 2022 to 15 Dec 2022.